Mainboard · BSE and NSEDraft filed
ARAGEN LIFE SCIENCES LIMITED IPO: dates, price band, lot size, objects of the issue
Get updates on this IPO
Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.Dates, allotment, listing and analyst views. Stop anytime.
By continuing you agree to the Terms and Privacy policy
Key facts
- Price band
- Not announced
- Lot size
- Not announced
- Lot amount at the upper band
- Not announced
- Issue size at the upper band
- Not announced
- Offer for sale
- 2,73,29,192 shares (Amount not stated in the draft)
- DRHP dated Wed 26 Aug 2026, page 83
- Bid dates
- Not announced
- Listing date
- Not announced
- Proposed exchanges
- BSE and NSE
Timeline (IST)
- Draft filedTue 1 Sep 2026 confirmedDRHP dated Wed 26 Aug 2026
- OpensDates to be announced
- ClosesDates to be announced
- AllotmentDates to be announced
- Refund and unblockDates to be announced
- ListingDates to be announced
Objects of the issue
| Object | Amount |
|---|---|
| Repayment and/or pre-payment, in part or full of certain borrowings availed by our Company and Material Subsidiaries | ₹385.00 crore |
| Capital expenditure to be incurred by the Company for purchase of new equipment and machinery for the facilities in Hyderabad | ₹154.00 crore |
| Capital expenditure to be incurred by one of our Material Subsidiaries, namely Aragen Biologics Private Limited for purchase of new equipment and machinery for the facility in Bengaluru, Karnataka^ | ₹71.00 crore |
| General corporate purposes(1) | Not stated in the draft |
| Total | Not stated in the draft |
The offer for sale goes to the selling shareholders, not the company. DRHP dated Wed 26 Aug 2026, page 139
Company and promoters
As described in the DRHP
We are a fully integrated contract research, development and manufacturing organization (“CRDMO”) serving global innovator companies and emerging firms in the life sciences industry.
DRHP dated Wed 26 Aug 2026, page 239
Promoters
- Reddy Investment Trust
- Madhubani Investments Private Limited
- 3 individual promoters
DRHP dated Wed 26 Aug 2026, page 319
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 59.44% | Not stated in the DRHP |
| Public | 39.55% | Not stated in the DRHP |
DRHP dated Wed 26 Aug 2026, page 124
Financials (restated)
| Item | March 31, 2026 | March 31, 2025 | March 31, 2024 |
|---|---|---|---|
| Revenue from operations | ₹2,178.39 crore | ₹1,845.11 crore | ₹1,657.58 crore |
| Profit after tax | ₹257.64 crore | ₹180.38 crore | ₹160.10 crore |
| Net worth | ₹2,231.24 crore | ₹2,057.38 crore | ₹1,304.55 crore |
| Total borrowings | Not stated in the draft | Not stated in the draft | Not stated in the draft |
DRHP dated Wed 26 Aug 2026, page 87
Who is selling in the offer for sale
| Selling shareholder | Type | Shares offered | Amount at the upper band |
|---|---|---|---|
| Reddy Investment Trust | Other | 18,63,354 | Not announced |
| Individual shareholder | Individual | 6,21,118 | Not announced |
| WSCPVIII (Singapore) Pte. Ltd. | Company | 1,84,60,361 | Not announced |
| WSCPVIII EMP (Singapore) Pte. Ltd. | Company | 33,23,006 | Not announced |
| Goldman Sachs Capital Holdings III Pte. Ltd. | Company | 25,65,193 | Not announced |
| WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd. | Company | 4,96,160 | Not announced |
| Total offer for sale | Not stated in the draft | ||
DRHP dated Wed 26 Aug 2026, page 83
Peer comparison (as in the DRHP)
| Name of Company | Face Value (₹) Per Share | P/E (1) | EPS (₹) Basic | EPS (₹) Diluted | NAV (₹) Per Equity Share (2) | RoNW (%)(3) |
|---|---|---|---|---|---|---|
| Our Company* | 10 | [●]# | 11.94 | 11.74 | 107.47 | 11.75 |
| Sai Life Sciences Ltd | 1 | 80.04 | 16.63 | 16.43 | 118.38 | 15.13 |
| Anthem Biosciences Ltd | 2 | 77.58 | 10.55 | 10.43 | 54.30 | 21.68 |
| Syngene International Ltd | 10 | 49.03 | 7.87 | 7.87 | 122.81 | 6.62 |
Reproduced from the DRHP dated Wed 26 Aug 2026, page 164; InsightPier adds no figures
Risk factors
93 total- The business depends on drug companies continuing to outsource research, and most revenue comes from contract research (DRHP page 31)
- Most revenue comes from customers outside India, mainly North America and Europe (DRHP page 32)
- A small group of key customers brings in a large share of revenue (DRHP page 33)
- Facilities face strict quality rules and regulator and customer inspections; failures could bring regulatory action (DRHP page 34)
- The company relies on skilled scientific staff and may struggle to hire or keep them (DRHP page 36)